(Q32067250)

6 July 2017

1 reference

title

Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications (English)

1 reference

6 July 2017

1 reference

1 reference

Hilleman MR

1 reference

6 July 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

6 July 2017

1 reference

6 July 2017

1 reference

6 July 2017

issue

15-16

1 reference

6 July 2017

page(s)

1837-1848

1 reference

Identification of hepatitis B virus indigenous to chimpanzees

6 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Full-genome sequence analyses of hepatitis B virus (HBV) strains recovered from chimpanzees infected in the wild: implications for an origin of HBV.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Detection of hepatitis B virus infection in wild-born chimpanzees (Pan troglodytes verus): phylogenetic relationships with human and other primate genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Hepatitis B virus replication: novel roles for virus-host interactions.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Membrane structure of the hepatitis B virus surface antigen particle

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Hepadnaviruses and retroviruses share genome homology and features of replication

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Comparative biology and pathogenesis of AIDS and hepatitis B viruses: related but different

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Recombination between sequences of hepatitis B virus from different genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Relationships within and between genotypes of hepatitis B virus at points across the genome: footprints of recombination in certain isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Hepatitis B virus biology

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Naturally occurring variants of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Intrahepatic T cells in hepatitis B: viral control versus liver cell injury

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Hepatitis B virus mutants.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Clinical relevance of hepatitis B viral mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Human hepatitis B virus mutants: significance of molecular changes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

The hepatitis B virus e antigen cannot pass the murine placenta efficiently and does not induce CTL immune tolerance in H-2b mice in utero

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Infection of the fetus with hepatitis B e antigen via the placenta

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Do T cells "see" the hepatitis B core and e antigens differently?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

The secretory core protein of human hepatitis B virus is expressed on the cell surface

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Nitric oxide inhibits hepatitis B virus replication in the livers of transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Immune pathogenesis of hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Trans-activation of cellular genes by hepatitis B virus proteins: a possible mechanism of hepatocarcinogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Expression of mutated hepatitis B virus X genes in human hepatocellular carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Antiviral therapy for chronic hepatitis B and C. Which patients are likely to benefit from which agents?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Chronic hepatitis B: new therapies on the horizon?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Chronic hepatitis B virus infection: treatment strategies for the next millennium

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

New therapies for the treatment of chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Intracellular mRNA cleavage induced through activation of RNase P by nuclease-resistant external guide sequences.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Purified and inactivated human hepatitis B vaccine: progress report

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Synthesis and assembly of hepatitis B virus surface antigen particles in yeast

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Human hepatitis B vaccine from recombinant yeast

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Yeast recombinant hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

The heritage of hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Are booster immunisations needed for lifelong hepatitis B immunity?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Strategies to prevent and control hepatitis B and C virus infections: a global perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Status of hepatitis B immunization programmes in 1998

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

Nationwide vaccination: a success story in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

The Global Alliance for Vaccines and Immunization--a millennial challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900364-9

7 January 2021

10.1016/S0264-410X(00)00364-9

Identifiers

DOI

1 reference

6 July 2017

1 reference